These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25281617)

  • 1. Therapeutic silencing of KRAS using systemically delivered siRNAs.
    Pecot CV; Wu SY; Bellister S; Filant J; Rupaimoole R; Hisamatsu T; Bhattacharya R; Maharaj A; Azam S; Rodriguez-Aguayo C; Nagaraja AS; Morelli MP; Gharpure KM; Waugh TA; Gonzalez-Villasana V; Zand B; Dalton HJ; Kopetz S; Lopez-Berestein G; Ellis LM; Sood AK
    Mol Cancer Ther; 2014 Dec; 13(12):2876-85. PubMed ID: 25281617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of siRNA payloads to target KRAS-mutant cancer.
    Yuan TL; Fellmann C; Lee CS; Ritchie CD; Thapar V; Lee LC; Hsu DJ; Grace D; Carver JO; Zuber J; Luo J; McCormick F; Lowe SW
    Cancer Discov; 2014 Oct; 4(10):1182-1197. PubMed ID: 25100204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant KRAS is a druggable target for pancreatic cancer.
    Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.
    Ganesh S; Koser ML; Cyr WA; Chopda GR; Tao J; Shui X; Ying B; Chen D; Pandya P; Chipumuro E; Siddiquee Z; Craig K; Lai C; Dudek H; Monga SP; Wang W; Brown BD; Abrams MT
    Mol Cancer Ther; 2016 Sep; 15(9):2143-54. PubMed ID: 27390343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable and efficient transfection of siRNA for mutated KRAS silencing using novel hybrid nanoparticles.
    Lakshmikuttyamma A; Sun Y; Lu B; Undieh AS; Shoyele SA
    Mol Pharm; 2014 Dec; 11(12):4415-24. PubMed ID: 25340957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.
    Mao CQ; Xiong MH; Liu Y; Shen S; Du XJ; Yang XZ; Dou S; Zhang PZ; Wang J
    Mol Ther; 2014 May; 22(5):964-73. PubMed ID: 24496383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
    Mehta A; Dalle Vedove E; Isert L; Merkel OM
    Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
    Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Delivery with Imaging Assessment of siRNA Expressing Nanocassettes into Cancer.
    Chen W; Yang L
    Methods Mol Biol; 2016; 1372():49-59. PubMed ID: 26530914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.
    Chakravarty D; Roy SS; Babu CR; Dandamudi R; Curiel TJ; Vivas-Mejia P; Lopez-Berestein G; Sood AK; Vadlamudi RK
    Clin Cancer Res; 2011 Apr; 17(8):2250-9. PubMed ID: 21421858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.
    Zeng L; Li J; Li J; Zhang Q; Qian C; Wu W; Lin Z; Liang J; Chen Y; Huang K
    Pancreas; 2015 Mar; 44(2):250-9. PubMed ID: 25401377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA.
    Cho WY; Hong SH; Singh B; Islam MA; Lee S; Lee AY; Gankhuyag N; Kim JE; Yu KN; Kim KH; Park YC; Cho CS; Cho MH
    Eur J Pharm Biopharm; 2015 Aug; 94():450-62. PubMed ID: 26141346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection.
    Freeley M; Long A
    Biochem J; 2013 Oct; 455(2):133-47. PubMed ID: 24070422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.
    Ganesh S; Iyer AK; Morrissey DV; Amiji MM
    Biomaterials; 2013 Apr; 34(13):3489-502. PubMed ID: 23410679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents.
    Liu X; Madhankumar AB; Slagle-Webb B; Sheehan JM; Surguladze N; Connor JR
    Cancer Res; 2011 Mar; 71(6):2240-9. PubMed ID: 21385903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
    Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.
    Shen S; Mao CQ; Yang XZ; Du XJ; Liu Y; Zhu YH; Wang J
    Mol Pharm; 2014 Aug; 11(8):2612-22. PubMed ID: 24521262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
    Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
    Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.